Candriam Eqs L Biotech R GBP Cap
SpecialistPricing frequency
Daily
Dealing cut off time
10:45
Type
SICAV
Yield
–
NAV
£570.86
Income frequency
-
Ongoing charge
1.1%
Latest actual NAV date
12-11-2026
ISIN
LU1269736911
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/04/2026 | % of assets |
|---|---|
| Vertex Pharmaceuticals Inc | 4.07 |
| Gilead Sciences Inc | 3.99 |
| Alnylam Pharmaceuticals Inc | 3.90 |
| Amgen Inc | 3.81 |
| Regeneron Pharmaceuticals Inc | 3.54 |
| Biogen Inc | 3.46 |
| Insmed Inc | 3.07 |
| Revolution Medicines Inc Ordinary Shares | 2.91 |
| Roivant Sciences Ltd Ordinary Shares | 2.81 |
| Ascendis Pharma AS | 2.32 |
Investment objective
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.